TABLE 4.

rCPAF+IL-12 immunization reduces the development of oviduct pathology^a

Immunization	% Mice developing hydrosalpinx		Oviduct dilatation score (mean ± SD)	Cellular infiltration score (mean ± SD)
	Bilateral	Unilateral		PMNs	Mononuclear cells	Plasma cells
PBS (mock)	83	0	2.41 ± 0.23	1.28 ± 0.22	2.7 ± 0.26	1.58 ± 0.20
rCPAF+IL-12	0	33	0.66 ± 0.21	0.66 ± 0.17	0.79 ± 0.24	0.45 ± 0.07
rMOMP+IL-12	33	33	1.18 ± 0.23	1.12 ± 0.22	1.62 ± 0.49	1.00 ± 0.20
rIncA+IL-12	50	17	1.25 ± 0.21	0.79 ± 0.15	1.5 ± 0.34	0.70 ± 0.10
rCPAF+rMOMP+IL-12	0	17	0.5 ± 0.13	0.75 ± 0.25	0.83 ± 0.15	0.41 ± 0.13
rCPAF+rIncA+IL-12	0	0	0.5 ± 0.12	0.62 ± 0.14	0.65 ± 0.10	0.45 ± 0.11
rCPAF+rMOMP+rIncA+IL-12	17	17	0.67 ± 0.30	0.75 ± 0.11	0.75 ± 0.17	0.55 ± 0.12
HEL+IL-12	67	17	2.16 ± 0.33	1.41 ± 0.22	2.66 ± 0.27	1.75 ± 0.18

^aAnimals (six mice/group) were immunized with three doses of rCPAF+IL-12, rMOMP+IL-12, rIncA+IL-12, rCPAF+rMOMP+IL-12, rCPAF+rIncA+IL-12, rCPAF+rMOMP+rIncA+IL-12, HEL+IL-12, or PBS (mock immunized). One month after the final booster vaccination, mice were challenged i.vag. with 10⁵ IFU of C. muridarum. At day 80 following C. muridarum challenge, animals were euthanized, and tissues were collected for further analysis. The development of bilateral and unilateral hydrosalpinx was studied as a measure of gross pathology. Quantitative histopathological scoring of oviduct dilatation and cellular infiltration into the genital tracts following chlamydial challenge was also performed. Groups of animals vaccinated with rCPAF+IL-12, rCPAF+rMOMP+IL-12, rCPAF+rIncA+IL-12, or rCPAF+rMOMP+rIncA+IL-12 each displayed significantly reduced incidence of oviduct dilatation, but not groups vaccinated with rMOMP+IL-12 or rIncA+IL-12, compared to groups vaccinated with PBS (mock vaccinated) or HEL+IL-12 (P < 0.05 by ANOVA). Results are representative of two independent experiments.